Ocular Therapeutix (OCUL) Non-Current Assets (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Non-Current Assets of $26.9 million for Q2 2026, up 49.74% year-over-year from $18.0 million in Q2 2025, and up 1.34% on a QoQ basis from $26.5 million in Q1 2026.
Ocular Therapeutix (OCUL) Non-Current Assets (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Non-Current Assets for 14 years, with the latest figure at $26.9 million in Q2 2026.
- Non-Current Assets for Q2 2026 came in at $26.9 million, up 49.74% year-over-year; the trailing twelve-month figure through Jun 2026 was $103.3 million (up 46.48% YoY), and the FY2025 annual result was $25.9 million, up 52.99% from the prior year.
- Non-Current Assets grew to $26.9 million in Q2 2026, from $26.5 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $26.9 million in Q2 2026 and troughed at $12.7 million in Q2 2022.
- A 5-year average of $19.7 million and a median of $19.4 million in 2022 frame the typical range for Non-Current Assets.
- The widest annual swing landed in 2023, when Non-Current Assets jumped 71.35%; it then decreased 17.84% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $19.7 million in 2022, then climbed by 0.83% to $19.8 million in 2023, then decreased by 14.51% to $16.9 million in 2024, then jumped by 52.99% to $25.9 million in 2025, then grew by 3.71% to $26.9 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $26.9 million in Q2 2026, $26.5 million in Q1 2026, and $25.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 26.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.89 Mn |
| Mar 31, 2026 | 26.53 Mn |
| Dec 31, 2025 | 25.93 Mn |
| Sep 30, 2025 | 23.90 Mn |
| Jun 30, 2025 | 17.96 Mn |
| Mar 31, 2025 | 18.23 Mn |
| Dec 31, 2024 | 16.95 Mn |
| Sep 30, 2024 | 17.36 Mn |
| Jun 30, 2024 | 18.51 Mn |
| Mar 31, 2024 | 19.12 Mn |
| Dec 31, 2023 | 19.83 Mn |
| Sep 30, 2023 | 21.13 Mn |
| Jun 30, 2023 | 21.85 Mn |
| Mar 31, 2023 | 21.41 Mn |
| Dec 31, 2022 | 19.66 Mn |
| Sep 30, 2022 | 12.96 Mn |
| Jun 30, 2022 | 12.75 Mn |
| Mar 31, 2022 | 12.97 Mn |
| Dec 31, 2021 | 13.59 Mn |
| Sep 30, 2021 | 13.81 Mn |